ACN Stock: Why The Discount May Not Last
At $185.28, Accenture (ACN) looks set up for roughly 44% of upside over the next three years under a moderate recovery scenario. Not a moonshot, but enough to matter if the math holds. The upside is powered primarily by steady earnings growth, while a modest re-rating from depressed multiples provides an additional tailwind.
Here is the operational reality the math is built on:
| ACN | |
|---|---|
| Sector | Information Technology |
| Industry | IT Consulting & Other Services |
| P/E Ratio | 14.6 |
| P/E Ratio 3Y Avg | 23.8 |
| LTM* Revenue Growth | 6.7% |
| 3Y Avg Revenue Growth | 4.8% |
| LTM* Net Margin | 10.7% |
| 3Y Peak Net Margin | 11.6% |
| 3Y Avg Net Margin | 11.0% |
*LTM: Last Twelve Months
How The Math Gets There
Three projections drive the upside number. Revenue compounds at 8.4% annually over three years—a clear step-up from the 6.7% trailing pace and 4.8% three-year average that assumes recent recovery momentum builds further. Net margin holds near today’s 10.7%. The multiple chips in modestly: today’s 14.6x re-rates partially toward the 3-year average, landing near 16.3x.
- The Gap Between ACN Stock And Its Own Numbers
- Accenture Stock Trades At A Discount While The Company Buys Its Growth
- ACN: Priced Like A Decline, Paying Like A Machine
- The Hidden Turbulence Priced Into Accenture Stock
- What ACN Holders Got Paid While The Stock Fell Behind
- ACN Got Cheaper. The Business Did Not Get Worse
Put those three together and earnings move from $7.8B to roughly $10.0B, a 29% jump. Apply the projected multiple and the stock lands near $266.93, roughly 44% above today.
If You’re Buying ACN At Today’s Price
You are paying for a story: that the market eventually recognizes the business has not deteriorated the way today’s discounted 14.6x implies. You are paying for operational execution: revenue must accelerate past recent averages while margins hold firm. The risk is a quarter that legitimately validates the discount.
The case rests on durable earnings delivery, requiring only a modest valuation thaw rather than an aggressive multiple re-rating.
Should You Invest In Accenture?
For a different read on ACN, see our recent piece The Gap Between ACN Stock And Its Own Numbers.
A careful 3-year case on a single name is still a concentrated bet, as historical volatility across past market crises shows. Investors who build analyses like this on individual positions often want the same framework running across a diversified book, partly for discipline, partly because even the cleanest single-stock thesis can break for reasons the math does not capture.
If it is exposure to technology as a whole you want rather than this one name, our ETF Scorecard ranks the technology funds. Going broader than any one sector, to a quality-first mix across the whole market, is where the portfolio below comes in.
The Trefis High Quality (HQ) Portfolio combines analytical rigor with a forward-looking view across 30 stocks, with a consistent selection framework and a sizing and re-balancing discipline designed to deliver upside without the single-name risk you just read through here.
By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.